Taho Pharmaceuticals (ROCO:6467) ROCE %: -64.37% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
35 GF Score
Price NT$113.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals ROCE %?

Taho Pharmaceuticals ROCO:6467 -4.22% 35 ROCE % is -64.37% as of Dec. 2025. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Taho Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was -64.37%.

Taho Pharmaceuticals  (ROCO:6467) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Taho Pharmaceuticals ROCE % Related Terms

Taho Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals ROCE % Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -29.63 -56.23 -60.01 -44.34 -44.69

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.00 -60.49 -47.73 -29.17 -64.37
ROCO:6467
35GF Score
Taho Pharmaceuticals Ltd ROCO:6467
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals ROCE % Calculation

Taho Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-213.871/( ( (560.696 - 33.063) + (455.595 - 26.042) )/ 2 )
=-213.871/( (527.633+429.553)/ 2 )
=-213.871/478.593
=-44.69 %

Taho Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-284.528/( ( (465.769 - 11.323) + (455.595 - 26.042) )/ 2 )
=-284.528/( ( 454.446 + 429.553 )/ 2 )
=-284.528/441.9995
=-64.37 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -64.37% mean?
Taho Pharmaceuticals (ROCO:6467) has a ROCE % of -64.37% as of Dec. 2025.
Is Taho Pharmaceuticals' ROCE % too high?
Taho Pharmaceuticals' current ROCE % is -64.37%. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' ROCE % compare to ZTS and UTHR?
Taho Pharmaceuticals' ROCE % of -64.37% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.05, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taho Pharmaceuticals's current ROCE % is -64.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current ROCE % of -64.37%. The current ROCE % is -64.37%. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current ROCE % is -64.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score

Get the complete analysis for ROCO:6467

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$113.50
Price